Front Cover: Carborane-Based Analogs of Celecoxib and Flurbiprofen, their COX Inhibition Potential, and COX Selectivity Index (ChemMedChem 11/2025)

IF 3.4 4区医学 Q2 CHEMISTRY, MEDICINAL

ChemMedChem Pub Date : 2025-06-03 DOI:10.1002/cmdc.202581101

Lea Ueberham, Jonas Schädlich, Kim Schramke, Sebastian Braun, Christoph Selg, Markus Laube, Peter Lönnecke, Jens Pietzsch, Evamarie Hey-Hawkins

引用次数: 0

Abstract

An illustrative Eurasian jay, representing the COX-2 enzyme, selectively picks up two superior nido-carborane acorns (shown without caps), while ignoring inferior closo-carborane analogues (acorns with caps). The removal of one boron vertex (nido form) significantly enhances COX-2 inhibitory potency, highlighting their potential as novel anti-inflammatory drug candidates. More details can be found in article 10.1002/cmdc.202500166 by Evamarie Hey-Hawkins. Art by Christoph Selg.

Abstract Image

查看原文本刊更多论文

封面：塞来昔布和氟比洛芬的碳硼烷类类似物，它们的COX抑制潜能和COX选择性指数（ChemMedChem 11/2025）

一只欧亚松鸦，代表COX-2酶，选择性地挑选了两个优质的无碳硼烷橡子（如图中没有帽），而忽略了劣质的近碳硼烷类似物（有帽的橡子）。去除一个硼顶点（nido形式）显著增强了COX-2抑制效力，突出了它们作为新型抗炎候选药物的潜力。更多细节可以在10.1002/cmdc中找到。202500166作者：Evamarie Hey-Hawkins。艺术由Christoph Selg。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

ChemMedChem 医学-药学

CiteScore

6.70

自引率

2.90%

发文量

280

审稿时长

1 months

期刊介绍： Quality research. Outstanding publications. With an impact factor of 3.124 (2019), ChemMedChem is a top journal for research at the interface of chemistry, biology and medicine. It is published on behalf of Chemistry Europe, an association of 16 European chemical societies. ChemMedChem publishes primary as well as critical secondary and tertiary information from authors across and for the world. Its mission is to integrate the wide and flourishing field of medicinal and pharmaceutical sciences, ranging from drug design and discovery to drug development and delivery, from molecular modeling to combinatorial chemistry, from target validation to lead generation and ADMET studies. ChemMedChem typically covers topics on small molecules, therapeutic macromolecules, peptides, peptidomimetics, and aptamers, protein-drug conjugates, nucleic acid therapies, and beginning 2017, nanomedicine, particularly 1) targeted nanodelivery, 2) theranostic nanoparticles, and 3) nanodrugs. Contents ChemMedChem publishes an attractive mixture of: Full Papers and Communications Reviews and Minireviews Patent Reviews Highlights and Concepts Book and Multimedia Reviews.